News

News 07.12.2019 Zurich-Schlieren, Switzerland, December 7, 2019. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics to treat serious diseases, today announced a poster presentation at the American Society of Hematology 61st Annual Meeting in Orlando, FL, highlighting the activity of its tri-specific DARPin® drug candidate, MP0250, in patients undergoing...

External events
Event date: 16.01.2020 Donnerstag, 16. Januar 2020 14.00 bis 20.00 Uhr Startup Space by IFJ Institut für Jungunternehmen AG Wiesenstrasse 5, 8952 Schlieren Workshops: Development Documentation: Best Practices Ein erfolgreicher klinischer Produktlebenszyklus: die PMCF-Strategie Semantic Discovery & AI als Lösungsansatz in der Regulation Journey Aus der Praxis: Wie kann ich mein Produkt einfach CE-zertifizieren? «Outsourced QMS»...

News 04.12.2019 Schlieren (Zurich), Switzerland, December 3, 2019 – Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of Offered Shares and gross proceeds from the Rights Offering and Share Offering, first announced on November 19, 2019, in which a total of up to 6,405,022 new registered shares of...

Internal events
Event date: 03.02.2020 February 3, 2020 | 9am - 6pm Technopark Zurich, Switzerland The Cause of Health Medicine has largely focused on studying the cause of illness in search for cures. Although we have made dramatic advances in identifying specific causes of illness in individual patients, we know remarkably little how individuals stay healthy. Cause...

News 20.11.2019 URDORF (Zurich), Switzerland, November 18, 2019 / B3C newswire / -- Securecell today announced that it has introduced Sephara, a high performance in-situ filtration membrane for applications in bioprocess sampling and perfusion processes for use in selected bioprocess laboratories. Interested users can participate in an early access program for the...